A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus

Journal of Clinical Psychiatry

Volumn 65, Issue 6, 2004, Pages 857-863

  Koller, Elizabeth A ^a   Weber, Jena ^a   Doraiswamy, P Murali ^b   Schneider, Bruce S ^a,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c ASSOCIATION OF AMERICAN MEDICAL COLLEGES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; QUETIAPINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CHILD; COMORBIDITY; COMPARATIVE STUDY; DIABETIC KETOACIDOSIS; DRUG SURVEILLANCE PROGRAM; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MEDLINE; MENTAL DISEASE; MIDDLE AGED; NONKETOTIC DIABETIC COMA; PHARMACOEPIDEMIOLOGY; PRESCHOOL CHILD; SCHIZOPHRENIA; SEX RATIO; UNITED STATES;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIPSYCHOTIC AGENTS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA; MALE; MEDLINE; MENTAL DISORDERS; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; SCHIZOPHRENIA; SEX DISTRIBUTION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 4344566384     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0619     Document Type: Review

References (44)

1. Seroquel (quetiapine). Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2004: 685-689
2. Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002;17:115-119 (Pubitemid 34442192)
3. Denys D, Van Megan H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive compulsive disorder: an open-label study. J Clin Psychiatry 2002;63:700-703 (Pubitemid 34898434)
4. Fernandez HH, Trieschmann ME, Burke MA, et al. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002;63:513-515 (Pubitemid 34680360)
5. Glick ID, Murray SR, Vasudevan P, et al. Treatment with atypical antipsychotics: new indications and new populations. J Psychiatr Res 2001;35:187-191 (Pubitemid 32666214)
6. Molho EA, Factor SA. Parkinson's disease: the treatment of drug-induced hallucinations and psychosis. Curr Neurol Neurosci Rep 2001;1:320-328
7. Scharre DW, Chang SI. Cognitive and behavioral effects of quetiapine in Alzheimer disease patients. Alzheimer Dis Assoc Disord 2002;16:128-130 (Pubitemid 34627681)
8. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45 (Pubitemid 34151336)
9. Weizman R, Weizman A. Use of atypical antipsychotics in mood disorders. Curr Opin Investig Drugs 2001;2:940-945 (Pubitemid 32700336)
10. De Vane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40:509-522 (Pubitemid 32738658)
11. Potkin SG, Thrum PT, Alva G, et al. The safety and pharmacokinetics of quetiapine when co-administered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002;22:121-130 (Pubitemid 34289386)
12. Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001;21:89-93 (Pubitemid 32096756)
13. Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998;8:151-159 (Pubitemid 28550705)
14. Stigler KA, Potenza MN, McDougle CJ. Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 2001;3:927-942 (Pubitemid 34074818)
15. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(suppl 23):5-12 (Pubitemid 32952689)
16. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001;24:59-73 (Pubitemid 32113367)
17. Taylor DM, McAskill R. Atypical antipsychotics and weight gain: a systematic review. Acta Pychiatr Scand 2000;101:416-432 (Pubitemid 30365564)
18. Domon SE, Cargile CS. Quetiapine-associated hyperglycemia and hypertriglyceridemia [letter]. J Am Acad Child Adolesc Psychiatry 2002;41:495-496
19. Procyshyn RM, Pande S, Tse G. New-onset diabetes associated with quetiapine [letter]. Can J Psychiatry 2000;45:668-669 (Pubitemid 30825696)
20. Sneed KB, Gonzalez EC. Type 2 diabetes mellitus induced by an atypical antipsychotic medication. J Am Board Fam Pract 2003;16:251-254
21. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment [letter]. J Clin Psychiatry 1999;60:556-557 (Pubitemid 29413481)
22. Wilson DR, D'Souza L, Sarkar N, et al. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2002;59:1-6
23. Bettinger TL, Mendelson SC, Dorson PG, et al. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000;34:865-867 (Pubitemid 30471268)
24. Litovitz TL, Klein-Schwartz W, White S, et al. 1999 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2000;18:517-574
25. Kenny SJ, Aubert RE, Geiss LS. Prevalence and incidence of non-insulin dependent diabetes. In: Harris MI, Cowie CC, Stern MP, eds. Diabetes in America. 2nd ed. Publication no. 95-1468. Bethesda, Md: National Institutes of Health - National Institute of Diabetes, Digestive, and Kidney Diseases; 1995:47-67
26. Ammon HR, Orci L, Steinle J. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat. J Pharmacol Exp Ther 1973;187:423-429
27. Isojarvi JI, Tauboll E, Pakarinen AJ, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001;111:290-296 (Pubitemid 32885625)
28. Jallon P, Picard F. Bodyweight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-978 (Pubitemid 33097097)
29. Odinesen H, Gram L, Andersen T, et al. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-69 (Pubitemid 14065224)
30. Turnbull DM, Bone AJ, Tames FJ, et al. The effect of valproate on blood metabolite concentrations in spontaneously diabetic, ketoacidotic, BB/E Wistar rats. Diabetes Res 1985;2:45-48 (Pubitemid 15107129)
31. Garrido Serrano A, Guerrero Igea FJ, Lepe Jimenez JA, et al. Hyperinsulinemia in cirrhotic patients infected with hepatitis C [in Spanish]. Gastroenterol Hepatol 2001;24:127-131
32. Piquer S, Hernandez C, Enriquez J, et al. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med 2001;137:38-42 (Pubitemid 32102754)
33. Brescan DW. Risperidone and glucose intolerance. Presented at the 150th annual meeting of the American Psychiatric Association; May 17-22, 1997; San Diego, Calif. Abstract NR267:137
34. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with risperidone treatment? [letter] Psychosomatics 2000;41:369-370
35. Koller EA, Schneider B, Bennett K, et al. Clozapine-associated diabetes mellitus. Am J Med 2001;111:716-723
36. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841-852 (Pubitemid 34743435)
37. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus. Pharmacotherapy 2003;23:735-744
38. Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001;50:148-149 (Pubitemid 32728215)
39. Wirshing DA, Boyd JA, Meng LR, et al. The effect of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-865 (Pubitemid 35231725)
40. Koller EA, Cross JT, Doraiswamy PM, et al. Pancreatitis associated with atypical antipsychotics: from the FDA MedWatch surveillance system and published reports. Pharmacotherapy 2003;23:1123-1130 (Pubitemid 37158780)
41. Ardizzone TD, Bradley RJ, Freeman AM III, et al. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogues of clozapine. Brain Res 2001;923:82-90 (Pubitemid 34024939)
42. Dwyer DS, Liu Ye, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells. Neurosci Lett 1999;274:151-154 (Pubitemid 29462534)
43. Dwyer DS, Lu X-H, Bradley RJ. Cytotoxicity of conventional and atypical antipsychotic drugs in relation to glucose metabolism. Brain Res 2003;971:31-39 (Pubitemid 36412061)
44. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav 2003;75:255-260 (Pubitemid 36859808)